Inventor · disambiguated record
Peter Lichtlen
Also filed as: LICHTLEN PETER
10 granted patents·5 pending applications·37 citations·filing 2003–2021
86Inventor score
Files withESBATECH ALCON BIOMED RES UNIT4AUF DER MAUR ADRIAN2DELENEX THERAPEUTICS AG2EWERT STEFAN2SUCAMPO AG2
Top patents by PatentIndex Score
15 records- 0192US8067547B2Stable and soluble antibodies inhibiting TNFαEWERT STEFAN·Filed 2006·Granted Nov 29, 2011·21 cites·41 claims
- 0286US7902340B2Antibodies binding to the extracellular domain of the receptor tyrosine kinase ALKDELENEX THERAPEUTICS AG·Filed 2007·Granted Mar 8, 2011·9 cites·12 claims
- 0380US9683034B2Stable and soluble antibodies inhibiting TNFαESBATECH ALCON BIOMED RES UNIT·Filed 2016·Granted Jun 20, 2017·2 cites·19 claims
- 0478US8945563B2Method for treating glioblastoma using antibodies binding to the extracellular domain of the receptor tyrosine kinase ALKAUF DER MAUR ADRIAN·Filed 2011·Granted Feb 3, 2015·4 cites·16 claims
- 0570US8936785B2scFv antibodies which pass epithelial and/or endothelial layersAUF DER MAUR ADRIAN·Filed 2007·Granted Jan 20, 2015·1 cites·3 claims
- 0663US9315572B2Stable and soluble antibodies inhibiting TNF alphaESBATECH ALCON BIOMED RES UNIT·Filed 2014·Granted Apr 19, 2016·0 cites·18 claims
- 0762US9512411B2Nucleic acid encoding antibodies binding to the extracellular domain of the receptor tyrosine kinase ALKCELL MEDICA SWITZERLAND AG·Filed 2014·Granted Dec 6, 2016·0 cites·15 claims
- 0861US8691228B2Stable and soluble antibodies inhibiting TNFαESBATECH ALCON BIOMED RES UNIT·Filed 2012·Granted Apr 8, 2014·0 cites·20 claims
- 0959US8389693B2Stable and soluble antibodies inhibiting TNFαEWERT STEFAN·Filed 2011·Granted Mar 5, 2013·0 cites·7 claims
- 1052US2014234315A1scFv Antibodies Which Pass Epithelial and/or Endothelial LayersESBATECH ALCON BIOMED RES UNIT·Filed 2014·Application pending·0 cites
- 1150US2013281638A1Tricyclo compound-polymer conjugateSUCAMPO AG·Filed 2013·Application pending·0 cites
- 1250US2011002927A1Antigen-binding polypeptides against cartilage degenerationDELENEX THERAPEUTICS AG·Filed 2009·Application pending·0 cites
- 1350US2006019238A1Method for identifying protein-protein interactionsESBATECH AG·Filed 2003·Application pending·0 cites
- 1449US2023203162A1Multispecific antibodyNumab Therapeutics AG·Filed 2021·Application pending·0 cites
- 1543US8835571B2Fatty acid derivative-polymer conjugateSUCAMPO AG·Filed 2013·Granted Sep 16, 2014·0 cites·29 claims
Join the waitlist — get patent alerts
Get an alert when Peter Lichtlen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →